Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model: Comparative study with cyclosporine and FK 506

Journal of Heart and Lung Transplantation

Volumn 22, Issue 10, 2003, Pages 1107-1116

  Richter, Markus H C ^a,b   Zahn, Steffen ^b   Kraus, Marion ^b   Mohr, Friedrich Wilhelm ^a   Olbrich, Hans Georg ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Experimental Heart Transplant Group   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CD18 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTERY; ARTICLE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EPICARDIUM; GRAFT REJECTION; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE TRANSFUSION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RAT; STAINING; STATISTICAL ANALYSIS;

EID: 0141656289     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(03)00100-1     Document Type: Article

References (43)

1. Chan B., Elices M., Murphy E., Hemler M. Adhesion to vascular cell adhesion molecule 1 and fibronectin. J Biol Chem. 267:1992;8366-8370.
2. Adams D.H., Karnovsky M.J. Hypercholesterolemia does not exacerbate arterial intimal thickening in chronically rejecting rat cardiac allografts. Transplant Proc. 21:1989;437-439.
3. Breidahl A.F., Hickey M.J., Stewart A.G., Hayward P.G., Morrison W.A. The role of cellular adhesion molecules in surgery. Austral NZ J Surg. 65:1995;838-847.
4. Weis M., von Scheidt W. Cardiac allograft vasculopathy. A review. Circulation. 96:1997;2069-2077.
5. Orosz C.G., Ohye R.G., Pelletier R.P. Treatment with anti-vascular cell adhesion molecule 1 monoclonal antibody induces long-term murine cardiac allograft acceptance. Transplantation. 56:1993;453-460.
6. Korom S., Hancock W.W., Coito A.J., Kupiec-Weglinski J.W. Blockade of very late antigen-4 binding to fibronectin in allograft recipients. II. Treatment with connecting segment-1 peptides prevents chronic rejection by attenuating artheriosclerotic development and suppressing intragraft T cell and macrophage activation. Transplantation. 65:(6):1998;854-859.
7. Adams D.H., Tilney N.L., Collins I.J., Karnowsky M.J. Experimental graft arteriosclerosis. I. The Lewis to Fisher F344 allograft model. Transplantation. 53:1992;1115-1119.
8. Adams D.H., Whyner L.R., Karnovsky M.J. Experimental graft arteriosclerosis. Immunocytochemical analysis of lesion development. Transplantation. 56(4):1993;794-799.
9. Cramer D.V., Wu G.D., Chapman F.A., et al. Lymphocytic subsets and histopathologic changes associated with the development of heart transplant atherosclerosis. J Heart Lung Transplant. 11:1992;458-466.
10. Ono K., Lindsey E.S. Improved technique of heart transplantation in rats. Thorac Surg. 547:1969;225-228.
11. Hancock W.H., Whitley W.D., Tullius S.G., Heemann U.W., Wasowska B., Baldwin W.M., Tilney N.L. Cytokines, adhesion molecules and the pathogenesis of chronic rejection of rat renal allografts. Transplantation. 56:1993;643-650.
12. Reutzel-Selke A., Tullius S.G., Graser E., Nieminen-Kelha M., Jonas S., Bechstein W.O., Neuhaus P., Volk H.D. Mechanisms of tolerance induction in second renal allografts of a chronic rejection model. Transplant Int. 13:(Suppl1):2000;476-479.
13. Sucic M., Boban D., Markovic-Glamocak M., Uzarevic B., Zadro R., Petrovecki M., Ries S., Gjadrov K., Golemovic M., Stavljenic-Rukavina A., Labar B., Batinic D. Double immunoenzymatic APAAP staining for the detection of leukemia-associated immunophenotypes. J Hematother Stem Cell Res. 8:(6):1999;635-643.
14. Eberlein-Konig B., Jung C., Rakoski J., Ring J. Immunohistochemical investigation of the cellular infiltrates at the sites of allergoid-induced late-phase cutaneous reactions associated with pollen allergen-specific immunotherapy. Clin Exp Allergy. 29:(12):1999;1641-1647.
15. Richter M., Skupin M., Grabs R., Schramm D., Richter H., Olbrich H.G. New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model. J Heart Lung Transplant. 19:(11):2000;1047-1055.
16. Richter M., Westphal M., Maybaum B., Richter H., Skupin M., Mohr F.W., Olbrich H.G. TCV-116 reduces chronic rejection in a rat heterotopic cardiac transplant model. Transplant Proc. 31:(1):1999;106-107.
17. + T cells that exhibit a transendothelial migratory capacity. J Immunol 1995;154(7):3062-77.
18. Miller A.M., McPaden A.R., Wadsworth R.M., Wainwright C.L. Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis. Cardiovasc Res. 49:2001;838-850.
19. Richter M., Richter H., Skupin M., Mohr F.W., Olbrich H.G. Do vascular compartments differ in the development of chronic rejection? AT(1) blocker candesartan versus ACE blocker enalapril in an experimental heart transplant model. J Heart Lung Transplant. 20:(10):2001;1092-1098.
20. Matsumoto T., Saito E., Watanabe H., Fujioka T., Yamada T., Takahashi Y., Ueno T., Tochihara T., Kanmatsuse K. Influence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 139:(1):1998;95-106.
21. Johannson A., Moeller E. Evidence that the immunosuppressive effect of FK506 and cyclosporine are identical. Transplantation. 50:1990;1001-1007.
22. Sawada S., Suzuki G., Kawase Y., Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 139:1987;1797-1803.
23. Jiang H., Fujitsu T., Sakuma S., Ogawa T., Tamura K., Fujii Y., Akiyama S., Izumi S., Takahara S., Ishibashi M., Sonoda T., Shimomura K. Immunosuppressive effects of FK506 on rat renal allograft survival, in comparison with cyclosporine. Transplant Proc. 27:(1):1995;367-369.
24. Kunz J., Hall M.N. Cyclosporin A, FK506, and rapamycin more than just immunosuppression . Trends Biochem Sci. 18:1993;334-338.
25. Almawi W.Y., Melemedjian O.K. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant. 15:2000;1916-1918.
26. Steinmüller T.M., Gräf K.-J., Schleicher J., Leder K., Bechstein W.O., Mueller A.R., Dette K., Schulz E., Neuhaus P. The effect of FK506 versus cyclosporine on glucose and lipid metabolism a randomized trial . Transplantation. 58:1994;669-674.
27. Loss M., Winkler M., Schneider A., Brinkmann C., Manns M., Ringe B., Pichlmayr R. Influence of long-term cyclosporine or FK506 therapy on glucose and lipid metabolism in stable liver graft recipients. Transplant Proc. 27:1995;1136-1139.
28. Apanay D.C., Neylan J.F., Ragab M.S., Sgoutas D.S. Cyclosporine increases the oxidizability of low-density lipoprotein in renal transplant recipients. Transplantation. 58:1994;663-669.
29. Fung J.J., Alessiani M., Abu-Elmagd K., Todo S., Shaoiro R., Tzakis A., Van Thiel D., Armitage J., Jain A., McCauley J., Selby R., Starzl T.E. Adverse effects associated with the use of FK506. Transplant Proc. 23:1991;3105-3108.
30. Textor S.C., Wiesner R., Wilson D.J., Porayko M., Romero J.C., Burnett J.C., Gores G., Hay E., Dickson E.R., Krom R.A. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 55:1993;1332-1339.
31. Akita K., Dusting G.J., Hickey H. Suppression of nitric oxide production by cyclosporine A and FK506 in rat vascular smooth muscle cells. Clin Exp Pharmacol Physiol. 21:1994;231-233.
32. Marumo T., Nakaki T., Hisikawa K., Suzuki H., Kato R., Saruta T. Cyclosporine A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension. 25:(2):1995;764-768.
33. Dogan A., MacDonald T.T., Spencer J. Cyclosporine A enhances T cell-mediated induction of E-selectin. Eur J Immunol. 23:1993;2922-2926.
34. Blaheta R.A., Leckel K., Wittig B., Zenker D., Oppermann E., Harder S., Scholz M., Weber S., Schuldes H., Encke A., Markus B.H. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transplant Immunol. 6:(4):1998;251-259.
35. Renlund D.G., Gopinathan S.K., Kfoury A.G., Taylor D.O. Mycophenolate mofetil (MMF) in heart transplantation rejection prevention and treatment . Clin Transplant. 10:(1):1996;136-139.
36. Halloran P.F. Molecular mechanisms of new immunosuppressants. Clin Transplant. 10:1996;118-123.
37. Kauppinen H., Soots A., Krogerus L., Loginov R., Holma K., Ahonen J., Lautenschlager I. Sequential analysis of adhesion molecules and their ligands in rat renal allografts during the development of chronic rejection. Transplant Int. 13:(4):2000;247-254.
38. Miller A.M., McPhaden A.R., Wadsworth R.M., Wainwright C.L. Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis. Cardiovasc Res. 49:(4):2001;838-850.
39. Rao G.N., Berk B.C. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogen expression. Circ Res. 70:1992;593-599.
40. Neumann F.-J., Ott I., Gawaz M., et al. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol. 27:1996;819-824.
41. Totani L., Piccoli A., Pellegrini G., et al. Polymorphonuclear leukocytes enhance release of growth factors by cultured endothelial cells. Arterioscler Thromb. 14:1994;125-132.
42. Moser R., Schleiffenbaum B., Groscurth P., et al. Interleukin-1 an tumor necrosis factor stimulates endothelial cells to promote neutrophil passage. J Clin Invest. 83:1989;444-455.
43. Richter M., Hussain K., Lukas D., Selkinsky I., Richter H., Olbrich H.G., Autschbach R., Mohr F.W. Mycophenolate mofetil significantly reduces chronic rejection after heart transplantation in rats a comparative study with cyclosporin A and FK506 . Int J Immunother. 26:(3):2000;37-44.